What is RxSight's operating income?

RxSight's total operating income in 2025 was -$48.19 million, based on the following breakdown: Total Gross Profit: $103.01 million Total Operating Expenses: $151.20 million

RxSight (RXST) Financials

$4.52 -0.01 (-0.22%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$4.65 +0.13 (+2.88%)

As of 04:44 AM Eastern

Compare

Annual Income Statements for RxSight

This table shows RxSight's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	3.37	-59	-67	-49	-27	-39
Consolidated Net Income / (Loss)	28	-49	-67	-49	-27	-39
Net Income / (Loss) Continuing Operations	27	-59	-67	-49	-27	-39
Total Pre-Tax Income	28	-49	-67	-49	-27	-39
Total Operating Income	-35	-53	-63	-50	-37	-48
Total Gross Profit	1.71	4.52	21	54	99	103
Total Revenue	15	23	49	89	140	134
Operating Revenue	15	23	49	89	140	134
Total Cost of Revenue	13	18	28	35	41	31
Operating Cost of Revenue	13	18	28	35	41	31
Total Operating Expenses	37	57	85	104	136	151
Selling, General & Admin Expense	15	33	59	75	101	113
Research & Development Expense	22	24	26	29	34	39
Total Other Income / (Expense), net	63	-6.35	-3.43	1.50	9.45	9.31
Interest Expense	0.51	3.68	4.95	5.08	0.02	0.02
Interest & Investment Income	0.00	0.05	1.52	6.57	9.47	9.33
Income Tax Expense	0.06	0.01	0.01	0.02	0.05	0.07
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	-	-0.01	0.01	-0.02
Basic Earnings per Share	$0.91	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Weighted Average Basic Shares Outstanding	3.71M	13.63M	27.66M	34.46M	38.87M	40.85M
Diluted Earnings per Share	$0.15	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Weighted Average Diluted Shares Outstanding	5.53M	13.63M	27.66M	34.46M	38.87M	40.85M
Weighted Average Basic & Diluted Shares Outstanding	1.00	0.00	33.78M	36.99M	40.49M	41.27M

This table shows RxSight's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Income / (Loss) Attributable to Common Shareholders	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.13	-16	-12
Consolidated Net Income / (Loss)	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16	-12
Net Income / (Loss) Continuing Operations	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16	-12
Total Pre-Tax Income	-9.20	-9.09	-6.06	-6.33	-5.93	-8.17	-12	-9.81	-9.15	-16	-12
Total Operating Income	-11	-11	-8.33	-9.23	-8.63	-11	-14	-12	-11	-18	-14
Total Gross Profit	18	21	24	25	29	28	34	24	25	23	34
Total Revenue	29	30	35	35	40	38	34	30	33	31	34
Operating Revenue	29	30	35	35	40	38	34	30	33	31	34
Total Cost of Revenue	11	8.83	11	10	11	9.57	0.00	6.11	7.34	7.40	0.00
Total Operating Expenses	29	31	33	34	37	39	48	36	37	41	48
Selling, General & Admin Expense	21	23	24	26	28	29	29	27	28	32	30
Research & Development Expense	7.34	8.03	8.29	8.84	9.21	10	10	9.06	8.91	9.47	9.24
Other Operating Expenses / (Income)	-	-	-	-	-	-	8.45	-	-	-	7.86
Total Other Income / (Expense), net	1.66	1.58	2.27	2.90	2.70	2.50	2.25	2.37	2.19	1.95	1.76
Interest Expense	0.00	0.01	0.01	0.01	0.00	0.01	0.01	0.00	0.00	0.00	0.00
Interest & Investment Income	1.66	1.59	2.28	2.91	2.71	2.51	2.25	2.38	2.19	1.95	1.76
Income Tax Expense	-0.02	0.01	0.02	0.01	0.01	0.02	0.03	0.01	0.01	0.01	0.09
Basic Earnings per Share	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)	($0.29)
Weighted Average Basic Shares Outstanding	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M	41.49M
Diluted Earnings per Share	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)	($0.29)
Weighted Average Diluted Shares Outstanding	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M	41.49M
Weighted Average Basic & Diluted Shares Outstanding	36.99M	37.20M	39.68M	40.30M	40.49M	40.64M	40.92M	41.12M	41.27M	41.40M	41.59M

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	5.63	11	-13	-2.19	7.05	3.24
Net Cash From Operating Activities	-35	-45	-59	-42	-17	-16
Net Cash From Continuing Operating Activities	-35	-39	-59	-42	-17	-16
Net Income / (Loss) Continuing Operations	28	-49	-67	-49	-27	-39
Consolidated Net Income / (Loss)	28	-49	-67	-49	-27	-39
Depreciation Expense	3.85	3.98	3.88	4.08	3.58	3.27
Amortization Expense	-0.20	0.48	-0.72	-5.84	-8.98	-8.52
Non-Cash Adjustments To Reconcile Net Income	-59	7.64	12	18	25	34
Changes in Operating Assets and Liabilities, net	-7.85	-2.68	-7.41	-8.91	-9.16	-4.89
Net Cash From Investing Activities	16	-82	40	-22	-99	17
Net Cash From Continuing Investing Activities	16	-82	40	-22	-99	17
Purchase of Property, Plant & Equipment	-2.54	-1.94	-2.39	-4.81	-5.44	-3.83
Purchase of Investments	-98	-160	-213	-272	-337	-239
Sale and/or Maturity of Investments	116	80	255	255	243	260
Net Cash From Financing Activities	25	137	6.33	62	123	1.86
Net Cash From Continuing Financing Activities	25	18	6.33	62	123	1.86
Repayment of Debt	-0.69	-0.13	-0.15	-62	0.00	0.00
Repurchase of Common Equity	0.00	0.00	-0.59	-0.62	-0.77	0.00
Issuance of Debt	25	16	0.00	20	0.00	0.00
Issuance of Common Equity	0.00	0.00	7.83	106	129	3.95
Other Financing Activities, net	0.87	2.32	-0.76	-1.58	-4.83	-2.09
Effect of Exchange Rate Changes	-	-0.01	-0.01	0.01	-0.01	0.00
Cash Interest Paid	0.43	3.19	4.26	3.46	0.00	0.00
Cash Income Taxes Paid	0.06	0.02	0.00	0.01	0.02	0.06

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
Net Change in Cash & Equivalents	-0.17	23	-8.20	-7.73	0.02	11	12	-11	-9.68	-2.38	-4.22
Net Cash From Operating Activities	-8.30	-9.31	-4.03	0.65	-4.26	-8.83	-4.38	-1.19	-1.12	-11	-9.54
Net Cash From Continuing Operating Activities	-8.30	-9.31	-4.03	0.65	-4.29	-8.83	-4.38	-1.22	-1.12	-11	-9.54
Net Income / (Loss) Continuing Operations	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16	-12
Consolidated Net Income / (Loss)	-9.18	-9.10	-6.08	-6.34	-5.94	-8.19	-12	-9.82	-9.15	-16	-12
Depreciation Expense	1.05	1.12	0.81	1.13	0.52	0.78	0.79	0.85	0.85	0.83	1.00
Amortization Expense	-1.54	-1.48	-2.07	-2.76	-2.62	-2.40	-2.14	-2.14	-1.83	-1.85	-1.75
Non-Cash Adjustments To Reconcile Net Income	4.58	4.81	6.16	6.75	7.32	7.19	9.78	8.14	8.43	8.01	8.79
Changes in Operating Assets and Liabilities, net	-3.21	-4.65	-2.86	1.87	-3.57	-6.21	-1.01	1.75	0.58	-1.99	-5.48
Net Cash From Investing Activities	4.57	24	-116	-9.26	1.32	21	15	-9.00	-9.61	8.85	4.65
Net Cash From Continuing Investing Activities	4.57	24	-116	-9.26	1.32	21	15	-9.00	-9.61	8.85	4.65
Purchase of Property, Plant & Equipment	-1.59	-1.97	-1.52	-1.10	-0.85	-0.58	-1.54	-0.58	-1.14	-0.76	-1.96
Purchase of Investments	-44	-48	-159	-77	-53	-39	-34	-68	-98	-100	-93
Sale and/or Maturity of Investments	50	74	45	69	55	60	50	60	90	110	100
Net Cash From Financing Activities	3.56	7.99	111	0.88	2.98	-0.74	2.07	-0.53	1.06	-0.34	0.66
Net Cash From Continuing Financing Activities	3.56	7.99	111	0.88	2.98	-0.74	2.07	-0.53	1.06	-0.34	0.66
Issuance of Common Equity	3.58	10	112	3.84	2.99	0.70	2.07	0.13	1.06	0.14	0.67
Other Financing Activities, net	-0.04	-2.16	-0.01	-2.65	-0.01	-1.43	-0.00	-0.66	0.01	-0.48	-0.01
Effect of Exchange Rate Changes	0.01	-0.00	-0.00	0.01	-0.01	0.01	0.01	-0.00	-0.02	0.00	0.00
Cash Income Taxes Paid	-0.00	0.00	0.02	0.00	-0.00	0.00	0.07	-	-0.01	0.00	0.14

This table presents RxSight's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	101	193	150	183	319	312
Total Current Assets	82	176	135	168	294	287
Cash & Equivalents	14	24	12	9.69	17	20
Short-Term Investments	55	135	94	117	221	208
Accounts Receivable	2.87	4.86	11	20	30	23
Inventories, net	8.29	8.03	15	17	22	32
Prepaid Expenses	1.37	4.07	2.96	3.52	4.54	4.39
Plant, Property, & Equipment, net	13	11	10	11	12	13
Total Noncurrent Assets	5.89	5.21	5.47	3.30	12	11
Other Noncurrent Operating Assets	5.89	5.21	5.47	3.30	12	11
Total Liabilities & Shareholders' Equity	101	193	150	183	319	312
Total Liabilities	45	54	60	22	37	36
Total Current Liabilities	12	11	17	21	26	26
Accounts Payable	1.13	1.69	2.60	3.86	4.54	5.30
Accrued Expenses	4.17	7.86	13	15	20	17
Customer Deposits	-	-	-	-	-	0.00
Current Deferred Revenue	-	-	-	-	-	3.26
Other Current Liabilities	6.29	1.53	1.97	1.80	0.97	1.16
Total Noncurrent Liabilities	33	43	43	1.29	11	9.88
Capital Lease Obligations	5.08	3.64	2.86	1.21	11	9.88
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-431	138	90	160	281	276
Total Preferred & Common Equity	-431	138	90	160	281	276
Preferred Stock	-	-	0.00	0.00	0.00	0.00
Total Common Equity	-431	138	90	160	281	276
Common Stock	0.00	618	636	755	903	937
Retained Earnings	-431	-479	-546	-595	-622	-661
Accumulated Other Comprehensive Income / (Loss)	-0.00	-0.02	-0.10	-0.01	0.17	0.05

This table presents RxSight's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026
Period end date	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026	6/30/2026
Total Assets	203	195	182	183	305	310	313	309	309	304	353
Total Current Assets	188	180	168	169	281	287	288	284	284	279	327
Cash & Equivalents	11	8.75	9.86	33	24	17	28	40	30	18	13
Short-Term Investments	143	138	122	93	209	220	201	187	198	200	195
Accounts Receivable	13	13	15	22	26	25	31	28	24	22	79
Inventories, net	18	18	19	19	19	22	24	25	29	35	37
Prepaid Expenses	2.99	2.11	1.90	2.96	2.77	2.61	4.54	3.26	3.26	4.03	2.96
Plant, Property, & Equipment, net	9.80	11	10	12	12	12	13	13	13	13	14
Total Noncurrent Assets	5.06	4.28	3.64	2.99	12	11	12	12	12	12	11
Other Noncurrent Operating Assets	5.06	4.28	3.64	2.99	12	11	12	12	12	12	11
Total Liabilities & Shareholders' Equity	203	195	182	183	305	310	313	309	309	304	353
Total Liabilities	58	38	20	19	30	33	34	31	33	37	89
Total Current Liabilities	15	17	19	18	20	23	23	20	22	27	80
Accounts Payable	3.72	4.00	4.11	5.06	5.10	4.58	7.11	3.35	3.38	7.12	6.35
Accrued Expenses	9.18	11	13	12	14	17	15	16	18	19	16
Customer Deposits	-	-	-	-	-	-	-	-	-	-	50
Current Deferred Revenue	-	-	-	-	-	-	-	-	-	-	6.88
Other Current Liabilities	1.98	1.98	1.98	1.61	0.74	0.73	1.06	1.10	1.29	1.50	1.66
Total Noncurrent Liabilities	43	22	1.43	0.91	11	11	11	11	10	9.32	8.92
Capital Lease Obligations	2.34	1.84	1.35	0.91	11	11	11	11	10	9.32	8.92
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	145	157	161	164	275	277	279	278	276	267	263
Total Preferred & Common Equity	145	157	161	164	275	277	279	278	276	267	263
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	145	157	161	164	275	277	279	278	276	267	263
Common Stock	704	730	747	768	885	893	910	920	928	944	952
Retained Earnings	-559	-573	-585	-604	-610	-616	-630	-642	-652	-677	-689
Accumulated Other Comprehensive Income / (Loss)	-0.01	-0.07	-0.06	-0.05	-0.12	0.52	0.02	-0.12	0.06	-0.07	-0.06

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	27,353,915.00	-	-	-	41,116,640.00
DEI Adjusted Shares Outstanding	0.00	27,353,915.00	-	-	-	41,116,640.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-2.16	-	-	-	-0.95
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	53.92%	116.90%	81.77%	57.09%	-3.89%
EBITDA Growth	0.00%	-263.37%	-17.82%	14.09%	18.32%	-26.46%
EBIT Growth	0.00%	-301.11%	-14.08%	20.90%	26.41%	-30.75%
NOPAT Growth	0.00%	-4.56%	-19.95%	20.90%	26.41%	-30.75%
Net Income Growth	0.00%	-276.57%	-37.11%	27.19%	43.52%	-41.85%
EPS Growth	0.00%	-2,480.00%	32.49%	41.49%	49.65%	-33.80%
Operating Cash Flow Growth	0.00%	-27.00%	-31.63%	29.32%	59.26%	8.47%
Free Cash Flow Firm Growth	0.00%	0.00%	-14.30%	13.71%	-10.38%	23.71%
Invested Capital Growth	0.00%	37.10%	21.57%	27.06%	60.93%	3.55%
Revenue Q/Q Growth	0.00%	0.00%	18.53%	16.31%	9.07%	-5.35%
EBITDA Q/Q Growth	0.00%	0.00%	13.40%	6.04%	1.42%	-3.05%
EBIT Q/Q Growth	0.00%	0.00%	13.79%	7.63%	5.69%	-5.95%
NOPAT Q/Q Growth	0.00%	0.00%	-0.52%	7.63%	5.69%	-5.95%
Net Income Q/Q Growth	0.00%	0.00%	0.18%	11.69%	10.55%	-9.00%
EPS Q/Q Growth	0.00%	0.00%	-97.54%	18.02%	12.35%	-9.20%
Operating Cash Flow Q/Q Growth	0.00%	-1.12%	-9.55%	11.78%	19.25%	16.85%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.19%	0.51%	10.42%
Invested Capital Q/Q Growth	0.00%	0.00%	2.35%	11.08%	9.37%	-2.20%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	11.62%	19.99%	43.52%	60.36%	70.71%	76.60%
EBITDA Margin	212.90%	-225.97%	-122.74%	-58.01%	-30.17%	-39.74%
Operating Margin	-241.26%	-233.64%	-129.21%	-56.23%	-26.34%	-35.84%
EBIT Margin	188.03%	-245.67%	-129.21%	-56.23%	-26.34%	-35.84%
Profit (Net Income) Margin	187.87%	-215.50%	-136.22%	-54.57%	-19.62%	-28.96%
Tax Burden Percent	99.79%	100.02%	100.01%	100.04%	100.18%	100.17%
Interest Burden Percent	100.12%	87.71%	105.42%	97.01%	74.35%	80.67%
Effective Tax Rate	0.21%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-217.15%	-191.52%	-179.31%	-113.85%	-57.38%	-59.76%
ROIC Less NNEP Spread (ROIC-NNEP)	-376.44%	-176.42%	-154.20%	-99.49%	-56.44%	-57.41%
Return on Net Nonoperating Assets (RNNOA)	266.59%	141.33%	120.79%	75.00%	44.95%	45.77%
Return on Equity (ROE)	49.44%	-50.19%	-58.52%	-38.85%	-12.43%	-13.99%
Cash Return on Invested Capital (CROIC)	0.00%	-222.82%	-198.78%	-137.68%	-104.08%	-63.25%
Operating Return on Assets (OROA)	27.41%	-37.84%	-36.93%	-30.11%	-14.71%	-15.29%
Return on Assets (ROA)	27.39%	-33.19%	-38.94%	-29.22%	-10.96%	-12.36%
Return on Common Equity (ROCE)	-381.74%	75.63%	-58.52%	-38.85%	-12.43%	-13.99%
Return on Equity Simple (ROE_SIMPLE)	-6.40%	-35.22%	-74.25%	-30.31%	-9.76%	0.00%
Net Operating Profit after Tax (NOPAT)	-35	-37	-44	-35	-26	-34
NOPAT Margin	-240.76%	-163.55%	-90.45%	-39.36%	-18.44%	-25.08%
Net Nonoperating Expense Percent (NNEP)	159.29%	-15.10%	-25.11%	-14.36%	-0.94%	-2.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-33.34%	-21.69%	-8.82%	-11.81%
Cost of Revenue to Revenue	88.38%	80.01%	56.48%	39.64%	29.29%	23.40%
SG&A Expenses to Revenue	103.39%	145.20%	119.71%	83.97%	72.49%	83.77%
R&D to Revenue	149.43%	108.44%	53.02%	32.61%	24.56%	28.67%
Operating Expenses to Revenue	252.78%	253.64%	172.73%	116.58%	97.05%	112.43%
Earnings before Interest and Taxes (EBIT)	28	-56	-63	-50	-37	-48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	31	-51	-60	-52	-42	-53
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	2.23	3.91	9.02	4.93	1.55
Price to Tangible Book Value (P/TBV)	0.00	2.23	3.91	9.02	4.93	1.55
Price to Revenue (P/Rev)	8.01	13.62	7.17	16.23	9.90	3.19
Price to Earnings (P/E)	34.94	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.86%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	34.69	8.60	10.63	38.30	20.91	3.66
Enterprise Value to Revenue (EV/Rev)	38.46	8.49	5.89	14.82	8.29	1.56
Enterprise Value to EBITDA (EV/EBITDA)	18.06	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	20.45	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.53	0.31	0.48	0.01	0.04	0.04
Long-Term Debt to Equity	0.53	0.31	0.48	0.01	0.04	0.04
Financial Leverage	-0.71	-0.80	-0.78	-0.75	-0.80	-0.80
Leverage Ratio	1.81	1.51	1.50	1.33	1.13	1.13
Compound Leverage Factor	1.81	1.33	1.58	1.29	0.84	0.91
Debt to Total Capital	34.58%	23.89%	32.37%	0.79%	3.91%	3.46%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	34.58%	23.89%	32.37%	0.79%	3.91%	3.46%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	570.52%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-505.10%	76.11%	67.63%	99.21%	96.09%	96.54%
Debt to EBITDA	0.94	-0.85	-0.72	-0.02	-0.27	-0.18
Net Debt to EBITDA	-1.26	2.27	1.04	2.44	5.35	4.08
Long-Term Debt to EBITDA	0.94	-0.85	-0.72	-0.02	-0.27	-0.18
Debt to NOPAT	-0.83	-1.17	-0.97	-0.04	-0.44	-0.29
Net Debt to NOPAT	1.12	3.14	1.42	3.59	8.75	6.47
Long-Term Debt to NOPAT	-0.83	-1.17	-0.97	-0.04	-0.44	-0.29
Altman Z-Score	-2.53	0.10	-1.72	35.09	20.61	5.07
Noncontrolling Interest Sharing Ratio	872.07%	250.69%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	7.03	15.92	7.81	8.06	11.36	10.95
Quick Ratio	6.19	14.82	6.77	7.05	10.33	9.58
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-43	-49	-42	-47	-36
Operating Cash Flow to CapEx	-1,388.13%	-2,304.54%	-2,459.26%	-864.00%	-311.51%	-404.99%
Free Cash Flow to Firm to Interest Expense	0.00	-11.68	-9.93	-8.35	-2,228.55	-1,879.09
Operating Cash Flow to Interest Expense	-69.03	-12.14	-11.90	-8.19	-806.95	-816.37
Operating Cash Flow Less CapEx to Interest Expense	-74.00	-12.67	-12.38	-9.14	-1,066.00	-1,017.95
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.15	0.15	0.29	0.54	0.56	0.43
Accounts Receivable Turnover	5.12	5.85	6.20	5.70	5.56	5.03
Inventory Turnover	1.57	2.22	2.42	2.19	2.08	1.18
Fixed Asset Turnover	1.10	1.84	4.59	8.49	12.03	10.56
Accounts Payable Turnover	11.44	12.81	12.92	10.94	9.75	6.40
Days Sales Outstanding (DSO)	71.24	62.42	58.91	64.00	65.64	72.51
Days Inventory Outstanding (DIO)	233.19	164.77	150.78	166.71	175.58	310.65
Days Payable Outstanding (DPO)	31.91	28.50	28.25	33.38	37.44	57.06
Cash Conversion Cycle (CCC)	272.52	198.69	181.44	197.33	203.79	326.10
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	16	22	27	34	55	57
Invested Capital Turnover	0.90	1.17	1.98	2.89	3.11	2.38
Increase / (Decrease) in Invested Capital	0.00	6.04	4.81	7.34	21	1.97
Enterprise Value (EV)	564	192	288	1,320	1,160	210
Market Capitalization	118	308	351	1,446	1,386	428
Book Value per Share	($116.15)	$5.05	$3.24	$4.47	$6.98	$6.70
Tangible Book Value per Share	($116.15)	$5.05	$3.24	$4.47	$6.98	$6.70
Total Capital	85	182	133	162	293	286
Total Debt	29	43	43	1.29	11	9.88
Total Long-Term Debt	29	43	43	1.29	11	9.88
Net Debt	-39	-116	-63	-126	-226	-218
Capital Expenditures (CapEx)	2.54	1.94	2.39	4.81	5.44	3.83
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.93	5.89	12	20	31	33
Debt-free Net Working Capital (DFNWC)	70	165	117	148	268	261
Net Working Capital (NWC)	70	165	117	148	268	261
Net Nonoperating Expense (NNE)	-63	12	22	14	1.65	5.21
Net Nonoperating Obligations (NNO)	-39	-116	-63	-126	-226	-218
Total Depreciation and Amortization (D&A)	3.65	4.45	3.17	-1.59	-5.35	-5.25
Debt-free, Cash-free Net Working Capital to Revenue	6.30%	26.05%	23.50%	22.81%	21.96%	24.60%
Debt-free Net Working Capital to Revenue	476.22%	731.28%	239.40%	165.59%	191.49%	194.24%
Net Working Capital to Revenue	476.22%	731.28%	239.40%	165.59%	191.49%	194.24%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Adjusted Weighted Average Basic Shares Outstanding	0.00	13.63M	27.66M	34.46M	38.87M	40.85M
Adjusted Diluted Earnings per Share	$0.00	($3.57)	($2.41)	($1.41)	($0.71)	($0.95)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	13.63M	27.66M	34.46M	38.87M	40.85M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	33.78M	36.99M	40.49M	41.27M
Normalized Net Operating Profit after Tax (NOPAT)	-35	-37	-44	-35	-26	-34
Normalized NOPAT Margin	-240.81%	-163.55%	-90.45%	-39.36%	-18.44%	-25.08%
Pre Tax Income Margin	188.25%	-215.47%	-136.20%	-54.55%	-19.59%	-28.91%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	54.12	-15.07	-12.80	-9.87	-1,755.14	-2,536.37
NOPAT to Interest Expense	-69.29	-10.04	-8.96	-6.91	-1,228.60	-1,775.46
EBIT Less CapEx to Interest Expense	49.14	-15.60	-13.29	-10.81	-2,014.19	-2,737.95
NOPAT Less CapEx to Interest Expense	-74.26	-10.56	-9.45	-7.85	-1,487.65	-1,977.04
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.88%	-1.28%	-2.80%	0.00%

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Period end date	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	6/30/2026
DEI Shares Outstanding	-	-	-	-	-	40,490,542.00	40,636,981.00	40,915,963.00	41,116,640.00	41,266,335.00	41,396,609.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	40,490,542.00	40,636,981.00	40,915,963.00	41,116,640.00	41,266,335.00	41,396,609.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-0.20	-0.29	-0.24	-0.22	-0.38	-0.29
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	77.64%	68.75%	67.65%	59.08%	40.71%	28.41%	-3.58%	-14.09%	-18.92%	-18.48%	0.31%
EBITDA Growth	22.66%	16.49%	32.25%	16.30%	5.38%	-11.46%	-60.20%	-24.06%	-14.23%	-53.24%	5.43%
EBIT Growth	27.61%	18.53%	38.84%	26.26%	20.48%	-0.04%	-68.04%	-32.00%	-31.37%	-67.03%	1.66%
NOPAT Growth	27.61%	18.53%	38.84%	26.26%	20.48%	-0.04%	-68.04%	-32.00%	-31.37%	-67.03%	1.66%
Net Income Growth	41.21%	31.12%	55.96%	48.95%	35.29%	10.00%	-93.88%	-54.88%	-54.13%	-93.94%	-2.64%
EPS Growth	56.36%	40.48%	60.00%	54.29%	41.67%	20.00%	-81.25%	-50.00%	-57.14%	-90.00%	0.00%
Operating Cash Flow Growth	40.08%	47.60%	46.63%	108.14%	48.68%	5.12%	-8.67%	-282.62%	73.80%	-23.31%	-117.96%
Free Cash Flow Firm Growth	2.42%	34.90%	-67.23%	-96.84%	-81.04%	-118.74%	31.64%	36.73%	63.37%	64.58%	34.78%
Invested Capital Growth	27.06%	17.10%	66.43%	63.45%	60.93%	54.40%	16.23%	15.81%	3.55%	-3.65%	3.80%
Revenue Q/Q Growth	28.74%	3.26%	18.21%	1.22%	13.88%	-5.77%	-11.24%	-9.80%	7.47%	-5.26%	9.22%
EBITDA Q/Q Growth	12.54%	2.72%	13.13%	-13.25%	1.12%	-14.07%	-24.85%	12.30%	8.55%	-53.03%	22.95%
EBIT Q/Q Growth	13.28%	1.67%	21.90%	-10.72%	6.47%	-23.70%	-31.19%	13.03%	6.91%	-57.28%	22.77%
NOPAT Q/Q Growth	13.28%	1.67%	21.90%	-10.72%	6.47%	-23.70%	-31.19%	13.03%	6.91%	-57.28%	22.77%
Net Income Q/Q Growth	26.08%	0.84%	33.20%	-4.26%	6.31%	-37.93%	-43.91%	16.71%	6.76%	-73.56%	23.84%
EPS Q/Q Growth	31.43%	-4.17%	36.00%	0.00%	12.50%	-42.86%	-45.00%	17.24%	8.33%	-72.73%	23.68%
Operating Cash Flow Q/Q Growth	-4.00%	-12.14%	56.74%	116.14%	-755.38%	-107.32%	50.45%	72.87%	5.98%	-875.90%	12.42%
Free Cash Flow Firm Q/Q Growth	-12.46%	11.39%	-102.70%	2.55%	-3.43%	-7.07%	36.65%	9.82%	40.12%	-3.55%	-16.63%
Invested Capital Q/Q Growth	11.08%	14.56%	33.21%	-3.59%	9.37%	9.91%	0.28%	-3.94%	-2.20%	2.27%	8.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	61.77%	70.09%	69.51%	71.42%	71.59%	74.76%	74.89%	79.85%	77.48%	76.06%	100.00%
EBITDA Margin	-39.69%	-37.39%	-27.48%	-30.74%	-26.69%	-32.46%	-45.66%	-44.39%	-37.77%	-61.01%	-43.04%
Operating Margin	-37.97%	-36.15%	-23.89%	-26.13%	-21.46%	-28.17%	-41.63%	-40.14%	-34.77%	-57.71%	-40.81%
EBIT Margin	-37.97%	-36.15%	-23.89%	-26.13%	-21.46%	-28.17%	-41.63%	-40.14%	-34.77%	-57.71%	-40.81%
Profit (Net Income) Margin	-32.11%	-30.83%	-17.42%	-17.95%	-14.77%	-21.61%	-35.04%	-32.35%	-28.07%	-51.42%	-35.85%
Tax Burden Percent	99.80%	100.10%	100.26%	100.21%	100.20%	100.22%	100.27%	100.10%	100.07%	100.04%	100.73%
Interest Burden Percent	84.74%	85.20%	72.76%	68.56%	68.68%	76.56%	83.94%	80.52%	80.68%	89.06%	87.21%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-76.88%	-69.91%	-45.74%	-57.41%	-46.74%	-58.23%	-75.36%	-72.96%	-57.98%	-86.05%	-58.51%
ROIC Less NNEP Spread (ROIC-NNEP)	-75.20%	-68.53%	-45.60%	-57.48%	-46.80%	-57.81%	-74.46%	-72.38%	-57.43%	-84.45%	-57.33%
Return on Net Nonoperating Assets (RNNOA)	56.70%	52.29%	36.72%	46.77%	37.27%	44.71%	59.15%	58.06%	45.79%	65.96%	44.13%
Return on Equity (ROE)	-20.18%	-17.62%	-9.02%	-10.64%	-9.47%	-13.52%	-16.21%	-14.90%	-12.19%	-20.09%	-14.37%
Cash Return on Invested Capital (CROIC)	-137.68%	-106.90%	-120.31%	-115.10%	-104.08%	-94.15%	-67.37%	-72.83%	-63.25%	-61.02%	-65.66%
Operating Return on Assets (OROA)	-20.33%	-18.95%	-10.99%	-13.62%	-11.98%	-16.84%	-19.93%	-18.43%	-14.83%	-23.85%	-15.74%
Return on Assets (ROA)	-17.19%	-16.17%	-8.02%	-9.35%	-8.25%	-12.92%	-16.77%	-14.85%	-11.98%	-21.24%	-13.83%
Return on Common Equity (ROCE)	-20.18%	-17.62%	-9.02%	-10.64%	-9.47%	-13.52%	-16.21%	-14.90%	-12.19%	-20.09%	-14.37%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-27.14%	-13.36%	-11.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.60	-7.47	-5.83	-6.46	-6.04	-7.47	-9.80	-8.52	-7.94	-12	-9.64
NOPAT Margin	-26.58%	-25.31%	-16.72%	-18.29%	-15.02%	-19.72%	-29.14%	-28.10%	-24.34%	-40.40%	-28.57%
Net Nonoperating Expense Percent (NNEP)	-1.68%	-1.38%	-0.14%	0.07%	0.06%	-0.42%	-0.90%	-0.58%	-0.55%	-1.59%	-1.18%
Return On Investment Capital (ROIC_SIMPLE)	-4.70%	-	-	-	-2.06%	-2.57%	-3.40%	-2.98%	-2.78%	-4.51%	-3.54%
Cost of Revenue to Revenue	38.23%	29.91%	30.49%	28.58%	28.41%	25.24%	25.11%	20.15%	22.52%	23.94%	0.00%
SG&A Expenses to Revenue	74.05%	79.03%	69.63%	72.52%	70.15%	75.57%	86.14%	90.13%	84.93%	103.11%	90.15%
R&D to Revenue	25.69%	27.21%	23.77%	25.03%	22.90%	27.36%	30.37%	29.86%	27.31%	30.66%	27.38%
Operating Expenses to Revenue	99.74%	106.24%	93.40%	97.54%	93.04%	102.92%	116.52%	119.99%	112.24%	133.77%	140.81%
Earnings before Interest and Taxes (EBIT)	-11	-11	-8.33	-9.23	-8.63	-11	-14	-12	-11	-18	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-11	-9.59	-11	-11	-12	-15	-13	-12	-19	-15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	9.02	11.64	8.13	7.07	4.93	3.66	1.90	1.33	1.55	0.95	0.76
Price to Tangible Book Value (P/TBV)	9.02	11.64	8.13	7.07	4.93	3.66	1.90	1.33	1.55	0.95	0.76
Price to Revenue (P/Rev)	16.23	18.87	19.43	15.29	9.90	6.89	3.59	2.59	3.19	1.99	1.56
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	38.30	45.17	38.32	34.21	20.91	13.19	5.09	2.56	3.66	0.78	0.00
Enterprise Value to Revenue (EV/Rev)	14.82	17.64	17.50	13.52	8.29	5.42	2.12	1.06	1.56	0.36	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	0.01	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.03	0.03
Long-Term Debt to Equity	0.01	0.01	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.03	0.03
Financial Leverage	-0.75	-0.76	-0.81	-0.81	-0.80	-0.77	-0.79	-0.80	-0.80	-0.78	-0.77
Leverage Ratio	1.33	1.25	1.16	1.12	1.13	1.12	1.11	1.12	1.13	1.13	1.22
Compound Leverage Factor	1.13	1.06	0.84	0.77	0.78	0.86	0.93	0.90	0.91	1.01	1.07
Debt to Total Capital	0.79%	0.55%	3.73%	3.67%	3.91%	3.78%	3.68%	3.59%	3.46%	3.37%	3.27%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.79%	0.55%	3.73%	3.67%	3.91%	3.78%	3.68%	3.59%	3.46%	3.37%	3.27%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.21%	99.45%	96.27%	96.33%	96.09%	96.22%	96.32%	96.41%	96.54%	96.63%	96.73%
Debt to EBITDA	-0.02	-0.02	-0.24	-0.25	-0.27	-0.25	-0.22	-0.20	-0.18	-0.16	-0.15
Net Debt to EBITDA	2.44	2.51	4.95	5.29	5.35	5.02	4.40	4.19	4.08	3.48	3.38
Long-Term Debt to EBITDA	-0.02	-0.02	-0.24	-0.25	-0.27	-0.25	-0.22	-0.20	-0.18	-0.16	-0.15
Debt to NOPAT	-0.04	-0.03	-0.36	-0.39	-0.44	-0.43	-0.36	-0.32	-0.29	-0.24	-0.23
Net Debt to NOPAT	3.59	3.73	7.51	8.28	8.75	8.46	7.28	6.82	6.47	5.38	5.18
Long-Term Debt to NOPAT	-0.04	-0.03	-0.36	-0.39	-0.44	-0.43	-0.36	-0.32	-0.29	-0.24	-0.23
Altman Z-Score	35.80	56.24	42.85	34.00	20.90	16.75	8.67	5.17	5.46	2.26	-0.32
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.06	9.20	14.33	12.67	11.36	12.68	13.93	12.74	10.95	10.20	4.07
Quick Ratio	7.05	8.02	13.20	11.60	10.33	11.45	12.54	11.29	9.58	8.78	3.57
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-15	-13	-27	-26	-27	-29	-18	-17	-9.90	-10	-12
Operating Cash Flow to CapEx	-521.75%	-473.26%	-264.41%	58.93%	-502.95%	-1,536.00%	-284.71%	-204.30%	-98.15%	-1,434.91%	-487.63%
Free Cash Flow to Firm to Interest Expense	-4,978.57	-2,205.83	-4,471.18	-5,228.64	-6,759.83	-4,825.13	-3,668.02	-4,134.90	-2,476.05	-3,418.43	-3,987.00
Operating Cash Flow to Interest Expense	-2,767.00	-1,551.50	-671.17	130.00	-1,065.00	-1,472.00	-875.20	-296.75	-279.00	-3,630.33	-3,179.33
Operating Cash Flow Less CapEx to Interest Expense	-3,297.33	-1,879.33	-925.00	-90.60	-1,276.75	-1,567.83	-1,182.60	-442.00	-563.25	-3,883.33	-3,831.33
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.54	0.52	0.46	0.52	0.56	0.60	0.48	0.46	0.43	0.41	0.39
Accounts Receivable Turnover	5.70	5.91	5.90	6.32	5.56	5.65	5.47	5.74	5.03	4.77	2.39
Inventory Turnover	2.19	2.01	2.08	1.99	2.08	1.97	1.78	1.40	1.18	1.00	0.94
Fixed Asset Turnover	8.49	9.44	10.03	11.40	12.03	12.27	11.44	11.22	10.56	9.89	9.35
Accounts Payable Turnover	10.94	8.44	8.55	9.32	9.75	6.86	9.36	8.93	6.40	4.12	6.05
Days Sales Outstanding (DSO)	64.00	61.77	61.82	57.77	65.64	64.61	66.74	63.60	72.51	76.45	152.45
Days Inventory Outstanding (DIO)	166.71	181.27	175.60	183.01	175.58	184.91	205.45	259.86	310.65	364.03	387.30
Days Payable Outstanding (DPO)	33.38	43.26	42.70	39.16	37.44	53.22	38.98	40.85	57.06	88.67	60.38
Cash Conversion Cycle (CCC)	197.33	199.78	194.72	201.63	203.79	196.30	233.21	282.62	326.10	351.82	479.38
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	34	39	53	51	55	61	61	59	57	59	63
Invested Capital Turnover	2.89	2.76	2.74	3.14	3.11	2.95	2.59	2.60	2.38	2.13	2.05
Increase / (Decrease) in Invested Capital	7.34	5.77	21	20	21	21	8.54	8.02	1.97	-2.23	2.32
Enterprise Value (EV)	1,320	1,783	2,015	1,735	1,160	804	311	151	210	46	-0.35
Market Capitalization	1,446	1,908	2,238	1,962	1,386	1,022	528	368	428	254	200
Book Value per Share	$4.47	$4.43	$7.40	$6.99	$6.98	$6.90	$6.84	$6.74	$6.70	$6.48	$6.36
Tangible Book Value per Share	$4.47	$4.43	$7.40	$6.99	$6.98	$6.90	$6.84	$6.74	$6.70	$6.48	$6.36
Total Capital	162	165	286	288	293	290	289	286	286	277	272
Total Debt	1.29	0.91	11	11	11	11	11	10	9.88	9.32	8.92
Total Long-Term Debt	1.29	0.91	11	11	11	11	11	10	9.88	9.32	8.92
Net Debt	-126	-124	-223	-227	-226	-218	-217	-217	-218	-209	-200
Capital Expenditures (CapEx)	1.59	1.97	1.52	1.10	0.85	0.58	1.54	0.58	1.14	0.76	1.96
Debt-free, Cash-free Net Working Capital (DFCFNWC)	20	25	28	27	31	36	36	34	33	34	38
Debt-free Net Working Capital (DFNWC)	148	150	262	264	268	266	263	262	261	252	247
Net Working Capital (NWC)	148	150	262	264	268	266	263	262	261	252	247
Net Nonoperating Expense (NNE)	1.58	1.63	0.25	-0.12	-0.10	0.72	1.98	1.29	1.22	3.40	2.46
Net Nonoperating Obligations (NNO)	-126	-124	-223	-227	-226	-218	-217	-217	-218	-209	-200
Total Depreciation and Amortization (D&A)	-0.49	-0.37	-1.25	-1.63	-2.11	-1.63	-1.35	-1.29	-0.98	-1.02	-0.75
Debt-free, Cash-free Net Working Capital to Revenue	22.81%	24.61%	24.59%	21.05%	21.96%	24.50%	24.48%	23.98%	24.60%	26.65%	29.90%
Debt-free Net Working Capital to Revenue	165.59%	148.60%	227.13%	205.88%	191.49%	179.13%	179.17%	184.10%	194.24%	197.56%	193.56%
Net Working Capital to Revenue	165.59%	148.60%	227.13%	205.88%	191.49%	179.13%	179.17%	184.10%	194.24%	197.56%	193.56%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)	($0.29)
Adjusted Weighted Average Basic Shares Outstanding	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M	41.49M
Adjusted Diluted Earnings per Share	($0.24)	($0.25)	($0.16)	($0.16)	($0.14)	($0.20)	($0.29)	($0.24)	($0.22)	($0.38)	($0.29)
Adjusted Weighted Average Diluted Shares Outstanding	34.46M	36.84M	38.46M	39.79M	38.87M	40.51M	40.74M	40.97M	40.85M	41.31M	41.49M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.99M	37.20M	39.68M	40.30M	40.49M	40.64M	40.92M	41.12M	41.27M	41.40M	41.59M
Normalized Net Operating Profit after Tax (NOPAT)	-7.60	-7.47	-5.83	-6.46	-6.04	-7.47	-9.80	-8.52	-7.94	-12	-9.64
Normalized NOPAT Margin	-26.58%	-25.31%	-16.72%	-18.29%	-15.02%	-19.72%	-29.14%	-28.10%	-24.34%	-40.40%	-28.57%
Pre Tax Income Margin	-32.17%	-30.80%	-17.38%	-17.91%	-14.74%	-21.56%	-34.94%	-32.32%	-28.05%	-51.40%	-35.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-3,617.00	-1,778.33	-1,388.83	-1,845.20	-2,157.25	-1,779.00	-2,800.60	-3,044.50	-2,834.00	-5,943.00	-4,590.00
NOPAT to Interest Expense	-2,531.90	-1,244.83	-972.18	-1,291.64	-1,510.08	-1,245.30	-1,960.42	-2,131.15	-1,983.80	-4,160.10	-3,213.00
EBIT Less CapEx to Interest Expense	-4,147.33	-2,106.17	-1,642.67	-2,065.80	-2,369.00	-1,874.83	-3,108.00	-3,189.75	-3,118.25	-6,196.00	-5,242.00
NOPAT Less CapEx to Interest Expense	-3,062.23	-1,572.67	-1,226.02	-1,512.24	-1,721.83	-1,341.13	-2,267.82	-2,276.40	-2,268.05	-4,413.10	-3,865.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1.28%	-0.88%	-1.08%	-2.42%	-2.80%	-2.89%	-1.21%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

RxSight’s second-quarter 2026 results show improving sequential execution, but the company remains unprofitable and cash-flow negative. Revenue increased to $33.7 million from $30.9 million in Q1 2026, a 9% sequential gain, and was roughly flat compared with $33.6 million in Q2 2025. Revenue remains below the $40.2 million reported in Q4 2024, indicating that the broader growth trend is still uneven.

Profitability improved sequentially but not year over year. The operating loss narrowed to $13.8 million from $17.8 million in Q1 2026, while the net loss improved to $12.1 million, or $0.29 per share, from $15.9 million, or $0.38 per share. However, the Q2 2026 net loss was slightly larger than the $11.8 million loss recorded in Q2 2025. RxSight has reported a net loss in every quarter provided, and retained earnings declined to a deficit of $689.0 million.

The balance sheet remains a significant source of financial flexibility. Cash and short-term investments totaled approximately $209.0 million at June 30, 2026, compared with $212.4 million at the end of Q2 2025. Total liabilities were $89.4 million, including $8.9 million of capital lease obligations and no long-term debt. The current ratio was approximately 4.1, although accounts receivable rose sharply to $78.5 million from $22.4 million in the prior quarter, which may reflect timing or collection-related factors that investors should monitor.

Cash usage remains a concern. Operating cash flow was negative $9.5 million in Q2 2026, following negative $10.9 million in Q1. The company has generally generated negative operating cash flow across the periods provided, with investment purchases and maturities causing substantial quarter-to-quarter swings in reported investing cash flow. Weighted-average shares outstanding also increased to approximately 41.5 million from 38.5 million in Q2 2024, creating potential dilution for existing shareholders.

Sequential revenue recovery: Q2 2026 revenue rose 9% from Q1, suggesting some improvement in demand or shipment timing.
Narrower operating loss: The operating loss improved by approximately $4.1 million sequentially as revenue increased and selling, general and administrative expense declined.
Strong liquidity and limited debt: Cash and short-term investments of roughly $209 million substantially exceeded total liabilities of $89 million, while the company reported no long-term debt.
Investment portfolio activity: RxSight continues to purchase and mature large short-term investment positions. This supports liquidity management but makes quarterly cash-flow trends less representative of core operations.
Reported gross margin requires caution: Q2 2026 cost of revenue was listed as zero, producing a 100% gross margin, despite cost of revenue in the preceding quarter and comparable prior periods. Investors should verify whether this reflects a classification, reporting, or timing issue before treating it as a sustainable improvement.
Persistent net losses: RxSight has not reached profitability in the periods provided, and the Q2 2026 net loss remained approximately $12.1 million.
Continuing operating cash burn: Operating cash flow was negative $9.5 million in Q2 2026 and negative $20.4 million for the first half of 2026, increasing reliance on the company’s cash and investment portfolio.
Working-capital risk: Accounts receivable surged to $78.5 million from $22.4 million in Q1 2026, while total current liabilities also increased substantially due in part to $50 million of customer deposits. The conversion of these balances into revenue and cash bears monitoring.
Share dilution: Weighted-average shares increased over the multi-year period, while common stock rose to $952.4 million on the balance sheet, indicating that equity issuance and equity-based compensation have been important sources of funding.

10/15/26 03:18 AM ETAI Generated. May Contain Errors.

RxSight Financials - Frequently Asked Questions

According to the most recent income statement we have on file, RxSight's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

RxSight's net income appears to be on a downward trend, with a most recent value of -$38.94 million in 2025, compared with $27.58 million in 2020. The previous period was -$27.46 million in 2024. Find out what analysts predict for RxSight in the coming months.

RxSight's total operating income in 2025 was -$48.19 million, based on the following breakdown:

Total Gross Profit: $103.01 million
Total Operating Expenses: $151.20 million

Over the last 5 years, RxSight's total revenue changed from $14.68 million in 2020 to $134.48 million in 2025, a change of 816.2%.

In the past 13 quarters, RxSight's cash and equivalents has ranged from $8.75 million in Q2 2023 to $40.36 million in Q2 2025, and is currently $13.35 million as of their latest financial filing in Q2 2026.

RxSight had total debt of $9.88 million at the end of 2025, a 13.7% decrease from 2024, and a 66.5% decrease since 2020.

Over the last 5 years, RxSight's book value per share changed from -116.15 in 2020 to 6.70 in 2025.

Related Companies

Financial statements for NASDAQ:RXST last updated on 8/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Financials

Financials Breakdown Chart

Key Financial Trends

RxSight Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Financials

Annual Income Statements for RxSight

Quarterly Income Statements for RxSight

Annual Cash Flow Statements for RxSight

Quarterly Cash Flow Statements for RxSight

Annual Balance Sheets for RxSight

Quarterly Balance Sheets for RxSight

Annual Metrics And Ratios for RxSight

Quarterly Metrics And Ratios for RxSight

Financials Breakdown Chart

Key Financial Trends

RxSight Financials - Frequently Asked Questions

When does RxSight's fiscal year end?

How has RxSight's net income changed over the last 5 years?

What is RxSight's operating income?

How has RxSight's revenue changed over the last 5 years?

How much cash does RxSight have?

How much debt does RxSight have?

How has RxSight's book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools